

HEALTH PLAN POLICY	
Policy Title: Genetic Expression Profiling – Lung Cancer	Policy Number: MUM53 Revision: B
Department: Medical Management	Sub-Department: Utilization Management
Applies to Product Lines: <input type="checkbox"/> Medicaid <input checked="" type="checkbox"/> USFHP <input type="checkbox"/> Children’s Health Insurance Plan <input checked="" type="checkbox"/> Commercial Insured <input checked="" type="checkbox"/> Health Insurance Exchange <input type="checkbox"/> Non Insured Business <input checked="" type="checkbox"/> Medicare	
Origination/Effective Date: 10/09/2019	
Reviewed Date(s):	Revision Date(s): 08/26/2020, 08/17/2021

SCOPE:

This policy addresses Genetic Expression Profiling (GEP) in patients with pulmonary lesions identified by CAT scan.

DEFINITIONS AND ACRONYMS:

- **Communicable Disease Center (CDC)**
- **Computed Axial Tomography (CAT)**
- **Genetic Expression Profiling (GEP)**
- **National Comprehensive Cancer Network (NCCN)** – an alliance of 27 cancer centers.
- **Non Small Cell Lung Cancer (NSCLC)**

POLICY:

This is an investigational study without medical necessity.

RATIONALE:

Lung cancer is the most common cause of cancer mortality and the third most common malignancy. NCCN does not mention GEP as a tool for further evaluating pulmonary nodules. False negative results from GEP can delay diagnosis and contribute to poor outcomes. No prospective, randomized studies have been done to establish clinical utility.

REFERENCES:

- NCCN 2019 Algorithms for Lung Cancer
- CDC 2018 Incidence and Mortality of Lung Cancer

RELATED DOCUMENTS:

None

HEALTH PLAN POLICY

Policy Title: Genetic Expression Profiling – Lung Cancer

Policy Number: MUM53

Revision: B

REVISION HISTORY:

Revision	Date	Description of Change	Committee
New	10/09/2019	Initial release.	Executive Leadership
A	08/26/2020	Yearly review. No change to policy content.	Executive Leadership
B	08/17/2021	Yearly review. No change to policy content.	Executive Leadership